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Background: Gastric cancer is a serious public health problem in Northern Brazil and in the world due to its high
incidence and mortality. Despite the severity of the disease, more research is needed to better understand the
molecular events involved in this intestinal-type gastric carcinogenesis process. Since precancerous lesions precede
intestinal-type gastric cancer, here, we evaluated the hTERT, MYC, and TP53 mRNA and protein expression, as well as
TP33 copy number, in gastric preneoplastic lesions.
Methods: We evaluated 19 superficial gastritis, 18 atrophic gastritis, and 18 intestinal metaplasia from cancer-free
individuals of Northern Brazil. Quantitative reverse transcription PCR was used to analyze the mRNA expression and
immunohistochemical methods were used to assess protein immunoreactivity in tissue samples. The number of
TP53 gene copies was investigated in gastric diseases by quantitative PCR.
Results: We observed hTERT, MYC, and p53 immunoreactivity only in intestinal metaplasia samples. The
immunoreactivity of these proteins was strongly associated with each other. A significantly higher MYC mRNA
expression was observed in intestinal metaplasia compared to gastritis samples. Loss of TP53 was also only detected
in intestinal metaplasia specimens.
Conclusions: We demonstrated that hTERT, MYC, and TP53 are deregulated in intestinal metaplasia of individuals
from Northern Brazil and these alterations may facilitate tumor initiation.
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Gastric cancer is the fourth most common cancer and
the second leading cause of cancer-related death world-
wide [1]. In Northern Brazil, gastric cancer is the second
most frequent neoplasia among males and the third in
females [2]. Some histopathological lesions precede well-
differentiated or intestinal-type gastric cancer. These
neoplasia types progress through a number of sequential
steps beginning with superficial gastritis, followed by
chronic atrophic gastritis, intestinal metaplasia, intrae-
pithelial neoplasia, and finally, carcinoma [3]. Although* Correspondence: mariana.morf@epm.br
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reproduction in any medium, provided the orthis neoplasia is a serious public health problem in
Northern Brazil and in the world, little is known about
the molecular events involved in the gastric carcinogen-
esis process. A better understanding of the critical
alterations implicated in tumor initiation is necessary to
reduce the mortality rates through early diagnosis and
treatment.
Cell immortalization has been reported as an import-
ant event in carcinogenesis. This process requires activa-
tion of telomerase, an enzyme essential for stabilizing
telomere length. Telomerase activation is described in
about 90% of human cancers, while most normal tissues
contain inactivated telomerase [4]. In the absence of
genome checkpoint functions, telomere dysfunction accel-
erates genomic instability, facilitating tumor initiation [5].
This genomic instability caused by telomere dysfunctiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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omerase activation. Subsequently, telomeres in these
initiated cells undergo further progressive shortening, gen-
erating rampant chromosomal instability and threatening
cell survival. Telomerase activation occurs at this stage to
stabilize the genome and confer unlimited proliferative
capacity upon the emerging and evolving cancer cell.
Therefore, cells that have acquired telomerase activity can
obtain the capacity for cancer progression [6].
Transcriptional regulation of hTERT (the catalytic sub-
unit of telomerase) gene is the major mechanism for
cancer-specific activation of telomerase. Several factors
have been reported to directly or indirectly regulate the
hTERT promoter, including cellular transcriptional acti-
vators, such as MYC, as well as the repressors, such as
p53 (see review [6]).
The MYC proto-oncogene has been described as a key
in the gastric carcinogenic process [7]. MYC protein has
an effect on about 15% of genes in the human genome
[8]. MYC activates several genes involved in cell cycle
regulation, metabolism, ribosome biogenesis, protein
synthesis, and mitochondrial function, while it consist-
ently represses genes involved in cell growth arrest and
cell adhesion, and also has a direct role in the control of
DNA replication [9]. Among the MYC target genes are
hTERT as well as TP53 [9].
TP53 is a key tumor suppressor gene in the carcino-
genesis process [10] acting in the DNA damage response
and apoptosis, as well as a regulator of cell metabolism
[11]. TP53 somatic alteration is described in approxi-
mately 50% of human cancers, including gastric cancer
[10]. Moreover, the loss of the TP53 locus is a common
finding in gastric neoplasias of individuals from Northern
Brazil [12].
The aim of the present study was to determine
whether hTERT, MYC, and TP53 mRNA expression, as
well as their protein products, are deregulated in gastric
preneoplastic lesions from cancer-free individuals of
Northern Brazil. The number of TP53 gene copies was
also evaluated in gastric diseases.
Results
hTERT, MYC, and p53 immunostaining was only detected
in intestinal metaplasia samples (Figure 1, Table 1). The fre-
quency of hTERT (χ2 = 19.243, df = 2, p< 0.001, by Pearson
Chi-square, V=0.592), MYC (χ2 =19.243, df =2, p< 0.001,
V=0.592), and p53 (χ2 = 13.844, df =2, p=0.001, V=0.502)
immunoreactivity differed among groups (Table 1). Using
the Bonferroni correction, a series of Fisher exact tests
demonstrated that the frequency of hTERT (p=0.001, OR=
1.9), MYC (p=0.001, OR=1.9), and p53 (p=0.01, OR=
1.58) immunoreactivity was higher in intestinal metaplasia
than in superficial gastritis. Intestinal metaplasia samples
also presented a higher frequency of hTERT (p=0.001,OR=1.8), MYC (p=0.001, OR=1.8), and p53 (p=0.008,
OR=1.5) immunoreactivity compared to atrophic gastritis
specimens. hTERT was strongly associated with MYC
(χ2 =40.086, df =1, p< 0.001, V=0.854, OR=0.024) and
p53 (χ2 =39.566, df =1, p< 0.001, V=0.848, OR=0.041)
immunoreactivity. MYC and p53 immunoreactivity was
also strongly associated (χ2 =25.638, df = 1, p< 0.001,
V=0.683, OR=0.073). Five of 18 (27.8%) intestinal meta-
plasia samples presented immunoreactivity for the three
studied proteins.
We observed a significant difference in MYC
(F = 2,52 = 41.172, p< 0.001, by ANOVA test, η
2 = 0.613)
mRNA expression among the studied groups (Table 1).
Tukey post-hoc analyses revealed that MYC mRNA ex-
pression was higher in intestinal metaplasia than super-
ficial (p< 0.001) and atrophic (p< 0.001) gastritis. A
1.5-fold increase in MYC expression was detected in
83.3% of intestinal metaplasia samples. The MYC mRNA
expression tended to be higher in samples with H. pylori
than samples without this pathogen (T53 =−1.934,
p = 0.058, by Student test, r = 0.257). MYC and TP53
mRNA expression were not correlated (p= 0.334,
r = 0.133). hTERT was weakly correlated to MYC and
TP53 mRNA expression (p= 0.047, r = 0.267; p = 0.028,
r = 0.296, respectively).
Higher hTERT and MYC mRNA expression was asso-
ciated with MYC immunoreactivity (T53 =−3.218, p=0.002,
by Student test, r = 0.398; T53 =−-7.429, p< 0.001,
r = 0.701, respectively). Higher hTERT, MYC, and TP53
mRNA expression was associated with hTERT
(T53 =−3.658, p=0.001, r =0.442; T53=−5.88, p< 0.001,
r = 0.621; T53=−2.316, p=0.024; r = 0.298, respectively) and
p53 (T53=−2.495, p=0.016, r = 0.319; T53 =−4.64,
p< 0.001, r = 0.530; T53 =−2.674, p=0.010; r = 0.339, re-
spectively) immunoreactivity.
One sample of superficial gastritis presented 3 copies of
TP53 and this case was excluded from the CNV statistical
analyses. Loss of TP53 copies was observed only in the
group of intestinal metaplasia samples (Table 1). The fre-
quency of TP53 loss was significantly higher in intestinal
metaplasia samples compared to gastritis specimens
(χ2 = 6.353, df = 1, p = 0.033, by Fisher exact test, V= 0.343,
OR= 2.4). The loss of TP53 copies was associated with
hTERT (χ2 = 18.265, df = 1, p = 0.002, V=0.582; OR= 1.6)
and p53 (χ2 = 9.926, df = 1, p = 0.03, V= 0.429, OR= 1.47)
immunoreactivity. However, this analysis should be con-
sidered with care since only 3 cases presented loss of
TP53 copies.
Discussion
Telomerase activation is thought to be essential for the
stabilization of telomere length, through which
immortalization and oncogenesis are achieved, but little
is known about the regulation of the hTERT subunit in
Figure 1 Immunostaining of hTERT, MYC and p53. (A) Absence of hTERT staining in atrophic gastritis (100×); (B) hTERT immunoreactivity in
intestinal metaplasia (400×); (C) Atrophic gastritis without MYC immunoreactivity (100×); (D) MYC immunopositivity in intestinal metaplasia (400×);
(E) Absence of p53 immunoreactivity in atrophic gastritis (100×); (F) negative control (400×).
Silva et al. BMC Gastroenterology 2012, 12:85 Page 3 of 8
http://www.biomedcentral.com/1471-230X/12/85human precancerous gastric lesions. In the present
study, we observed that hTERT, MYC, and p53 immu-
noreactivity was only present in intestinal metaplasia
samples. In addition, we detected a strong association
among these three proteins and 27.8% of intestinal meta-
plasia samples presented immunostaining of the three
studied proteins. MYC is a transcriptional activator and
p53 is a repressor of hTERT expression [6]. Some studies
favored the view that MYC drove initial proliferation
and subsequent differentiation, concomitant with the ac-
tivation of the p53 G2 checkpoint and also demonstrated
that inactivation of the p53-Rb pathway is required for
immortalization through overepression of MYC [13,14].
Thus, some cases of intestinal metaplasia may carry
short telomeres and due to this telomere dysfunction,
MYC stimulates hTERT expression. However, in the ab-
sence of genome checkpoint functions (i.e. p53mutations or TP53 deletion), this process will favor the
proliferation of immortalized cells carrying genetic and
epigenetic alterations and tumor initiation.
It is important to note that, although intestinal meta-
plasia precedes intestinal-type gastric cancer, only few
individuals with this preneoplastic lesion will develop
gastric tumors. Further investigation are necessary to
evaluate the role of hTERT, MYC, and p53 proteins –
alterations common described in gastric neoplasia – in
the disease progression, ideally with biopsies of intestinal
metaplasia and tumor from the same patients. These
biomarkers may be useful for the assessment of gastric
cancer risk if validated in a larger clinical study sets.
Some studies demonstrated that hTERT expression
increases with the sequential steps of intestinal-type
gastric carcinogenesis [15-19], suggesting that hTERT
deregulation represents an important step in the
Table 1 Clinicopathological characteristics, MYC, hTERT and TP53 expression, and TP53 copies in gastric samples
Superficial gastritis Atrophic gastritis Intestinal metaplasia
Gender
Male [N (%)] 12 (63.2) 11 (61.1) 12 (66.7)
Female [N (%)] 7(36.8) 7 (38.9) 6 (33.3)
Alcohol consumption
Negative [N (%)] 10 (52.6) 10 (55.6) 12 (66.7)
Positive [N (%)] 9 (47.4) 8 (44.4) 6 (33.3)
Cigarette smoking
Negative [N (%)] 10 (52.6) 12 (66.7) 9 (50)
Positive* [N (%)] 9 (47.4) 6 (33.3) 9 (50)
H. pylori infection
Negative [N (%)] 7 (36.8) 5 (27.8) 1 (5.6)
Positive [N (%)] 12 (63.2) 13 (72.2) 17 (94.4)
hTERT mRNA expression
RQ (Mean± SD) 1.092 ± 0.61 0.821 ± 0.47 1.184± 0.55
MYC mRNA expression
RQ (Mean± SD) 0.852± 0.51** 0.873± 0.28** 1.901± 0.49
TP53 mRNA expression
RQ (Mean± SD) 0.997 ± 0.59 0.847 ± 0.79 1.021± 0.61
hTERT immunoreactivity
Negative [N (%)] 19 (100) 18 (100) 10 (55.6)
Positive [N (%)] 0 (0)** 0 (0)** 8 (44.4)
MYC immunoreactivity
Negative [N (%)] 19 (100) 18 (100) 10 (55.6)
Positive [N (%)] 0 (0)** 0 (0)** 8 (44.4)
p53immunoreactivity
Negative [N (%)] 19 (100) 18 (100) 12 (66.7)
Positive [N (%)] 0 (0)** 0 (0)** 6 (33.3)
TP53 copies
2 copies [N (%)] 18 (100) 18 (100) 15 (83.3)
1 copy [N (%)] 0 (0) 0 (0) 3 (16.7)***
RQ: relative quantification.
*Patients smoking one or more cigarettes per day (range 1–20).
**Significantly different from intestinal metaplasia group.
***Gastritis was significantly different from intestinal metaplasia group.
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strated that 80% of gastric tumors and no non-
neoplastic gastric mucosa of individuals from Northern
Brazil presented hTERT immunoreactivity, suggesting
that hTERT may have an impact on the anti-telomerase
strategy for cancer therapy [20].
The detection of MYC immunoreactivity in intestinal
metaplasia of individuals from three Northern Brazil
populations corroborates previous studies of our group
that demonstrated the presence of MYC protein overex-
pression only in intestinal metaplasia and neoplastic tis-
sue from all patients with intestinal type gastric cancer,which is preceded by preneoplastic lesions [21-23], as
well as in intestinal metaplasia of non-human primates
treated with N-methyl-nitrosourea (MNU) [24]. On the
other hand, MYC immunoreactivity was described in
gastritis samples, as well as intestinal metaplasia, in
Asian populations [15,25-27].
Here, MYC immunoreactivity was strongly associated
with increased mRNA expression. To our knowledge,
this is the first study to sensitively quantify MYC mRNA
expression in precancerous gastric lesions. The increased
MYC expression in intestinal metaplasia supports a pre-
vious study of our group in non-human primates, in
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mRNA expression during the sequential steps of gastric
carcinogenesis in MNU-treated animals [24]. In these
animals, the mRNA expression increased about 3-fold in
intestinal metaplasia compared to normal gastric mu-
cosa. In addition, we previously reported that a signifi-
cant increase of MYC copy number was seen with the
evolution of carcinogenesis process in humans and non-
human primates [21,24], which may contribute to the
increased mRNA expression and protein immunoreac-
tivity. In addition, MYC amplification or trisomy of
chromosome 8, where MYC is located, was detected in
all human gastric cancer of individuals from Northern
Brazil [21-23,28-31], as well as in gastric cancer cell lines
established from the tumors of Brazilian patients
[32-35], supporting that MYC has a key role in gastric
carcinogenesis.
Previously we also reported the presence of p53
immunoreactivity in all intestinal-type gastric cancer of
individuals from Northern Brazil [12]. The p53 immu-
noreactivity usually depends on the accumulation of
mutated p53 proteins in the cell, which leads to a longer
half-life [36]. Some studies have demonstrated TP53
mutations in gastritis [37] and intestinal metaplasia
[38,39] as well as gastric cancer, which corroborates the
observation of p53 immunoreactivity in intestinal meta-
plasia samples of the studied population. The presence
of p53 immunostaining only in intestinal metaplasia cor-
roborates previous studies of literature [15,40]. However,
Targa et al. [41] reported p53 overexpression in 5/19
(26.3%) of chronic gastritis, 1/8 (12.5%) of atrophic gas-
tritis and 2/11 (18.2%) of intestinal metaplasia of indivi-
duals from Southeastern Brazil.
To our knowledge, few studies evaluated the number
of copies of TP53 in pre-neoplastic gastric lesions. Loss
of heterozygosity at the TP53 locus is one of the most
common mechanisms involved in this gene pathway de-
regulation. Loss of TP53 is a frequent finding in gastric
cancer [42]. Previously, our group demonstrated that the
loss of TP53 copies and aneusomy of chromosome 17,
where this gene is located, was present in all gastric can-
cer samples of individuals from Pará State, Northern
Brazil [12], and also in all gastric cancer cell lines estab-
lished from neoplasias in this population [33,43]. Here,
we observed TP53 deletion in 16.7% of intestinal meta-
plasia in individuals from Northern Brazil by qPCR. In a
Southeastern Brazilian population, it was described that
3/5 (60%) of intestinal metaplasia samples presented loss
of TP53 by fluorescence in situ hybridization (FISH)
assay [36]. Williams et al. [42] also reported that the de-
letion of TP53 was a common event in premalignant
stages of gastric carcinogenesis by FISH analyses. These
authors demonstrated that this alteration was about 3-
fold increased in intestinal metaplasia (N= 4) comparedto normal gastric tissue. Since TP53 is a critical tumor
suppressor gene in the carcinogenesis process, the loss
of this gene copy and its protein immunoreactivity in
the intestinal metaplasia stage may contribute for tumor
initiation.
Conclusions
In conclusion, hTERT, MYC, and TP53 are deregulated
in intestinal metaplasia of individuals from Northern
Brazil and these alterations may facilitate tumor initiation.
Methods
Clinical samples
Samples were obtained from cancer-free patients includ-
ing 19 with superficial gastritis, 18 with atrophic gastri-
tis, and 18 patients with intestinal metaplasia by
endoscopy. From each patient, normal tissue sample
were also collected. Samples were collected at endoscopy
services in Pará, Maranhão and Ceará States in Northern
Brazil. Informed consent with approval of the ethics
committee of the Federal University of Pará was
obtained. Tissue specimens were immediately frozen in
liquid nitrogen and kept at −80°C until RNA and DNA
extraction. All studied samples were negative for
Epstein-Barr infection by in situ hybridization method
[44]. The presence of Helicobacter pylori, a class I car-
cinogen, in gastric samples was detected by the PCR
assay for the urease gene [45]. Table 1 shows the clinico-
pathological characteristics of patients.
Immunohistochemistry
Immunohistochemical analyses were performed on
formalin-fixed, paraffin-embedded sections. Immunohis-
tochemical staining was performed on the paraffin sec-
tions according to Calcagno et al. [22] with primary
mouse monoclonal antibody against hTERT (dilution
1:50; clone 44 F12, Novocastra Laboratories Ltd, UK),
MYC (dilution 1:150; sc-40, Santa Cruz Biotechnology,
USA and ZymedW, USA), or p53 (dilution 1:50; Dakocy-
tomation, USA). A universal peroxidase-conjugated sec-
ondary antibody kit (LSAB System, DakoCytomation,
USA) was used for the detection system, and diamino-
benzidine (DAB) was the applied chromogen. Positive
protein expression was defined as clear nuclear imunos-
taining in more than 10% of the cells.
mRNA expression
Total RNA was extracted with Tri-reagent (Applied Bio-
systems, USA) following the manufacturer’s instructions.
RNA concentration and quality were determined using
the NanoDrop spectrophotometer (Kisker, Germany) and
1% agarose gels. Complementary DNA was synthesized
using High-Capacity cDNA Archive (Applied Biosystems,
Poland).
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ated by quantitative reverse transcription PCR (qRT-
PCR) with primers and TaqMan probes purchased as
Assays-on-demand Products for Gene Expression (Ap-
plied Biosystems, USA). GAPDH gene was selected as an
internal control for RNA input and reverse transcription
efficiency. All real-time qRT-PCR reactions were per-
formed in triplicate for all target genes (hTERT:
Hs00972656_m1; MYC: Hs00153408_m1; TP53:
Hs01034249_m1) and the internal control (GAPDH:
NM_002046.3).
Relative quantification (RQ) of the gene expression
was calculated according to Livak and Schmittgen [46].
In the present study, the corresponding normal tissue
sample was designated as a calibrator for superficial gas-
tritis, atrophic gastritis, or intestinal metaplasia sample
from each patient.
TP53 copy number variation (CNV)
Quantitative TaqMan CNV assays (Applied Biosystems,
USA) were used as a confirmation to FISH analysis. Du-
plex quantitative PCR (qPCR) was performed using the
FAM/MGB-labeled TaqMan probe for TP53 gene
(Hs06423639_cn) and VIC/TAMRA-labeled TaqMan
CNV RNAse P (#4403326) for the internal control. qPCR
reactions were performed in quadruplicate with genomic
DNA (gDNA) according to the manufacturer's protocol
and cycling conditions in 7500 Fast Real-Time PCR (Ap-
plied Biosystems, USA). Relative quantification analysis
was done to estimate the copy number for each sample
by using the Copy Caller Software V1.0 (Applied Biosys-
tems, USA). A known human gDNA (Promega, USA)
was used for calibration.
Data analysis
Chi-square test was performed to analyze hTERT, MYC,
and p53 immunostaining, as well as TP53 CNV data. To
take into account the multiple testing, Bonferroni cor-
rections were applied to adjust the Chi-squared p value
when necessary. Shapiro-Wilk normality test was used
to evaluate the normal distribution of mRNA expression
data and to determine subsequent use of appropriate
tests for statistical comparison. Data that were not nor-
mally distributed were transformed (z-score transform-
ation) for the analysis of variance in gene expression
such that they followed a normal distribution. Analyses
of variance in mRNA expression were performed by
one-way ANOVA followed by Tukey (homogeneity of
variances according to Levene test) post-hoc test. Chi-
square and Student’s T test were used to assess the relation-
ship between gene expression, protein immunoreactivity,
and CNV results and clinicopathological factors.
The effect size for Chi-square was based on Cramer’s
phi (V) and the effect size correlation directly from theStudent T test as “r” (Pearson correlation coefficient), in
which a value between 0.1-0.29 was determined as a
small effect size; 0.3-0.49 as a medium effect size; and
0.50 or above as a large effect size. The effect size for
ANOVA analyses was based on Eta Squared (η2), in
which values 0.15 and below were determined as a small
effect size; 0.16-0.40 as a medium effect size; and above
0.40 as a large effect size.
The correlation between hTERT, MYC, and TP53
mRNA expression was analyzed by the Pearson test, in
which a value below 0.30 was determined as a weak cor-
relation; 0.30-0.70 as a medium correlation; and above
0.70 as a strong correlation.
In all analyses, the confidence interval was 95% and
p values less than 0.05 were considered significant.
Abbreviations
CNV: Copy Number Variation; DAB: diaminobenzidine; gDNA: genomic DNA;
MNU: Nmethyl-nitrosourea; qPCR: quantitative PCR; qRT-PCR: quantitative
reverse transcription PCR; RQ: Relative Quantification.
Competing interests
All authors declare that they have no conflicts of interest.
Authors’ contributions
MFL, TCRS, PPA, MACS and RRB conceived and designed the experiments.
TCRS, MFL, DQC, RCM and MQN performed the experiments. TCRS, MFL,
DQC, CRT, ASK, NPCS, MACS, and RRB analyzed the data. NPCS, SHBR and
PPA contributed reagents/materials/analysis tools. MFL, TCRS, MACS and RRB
wrote the paper. All authors read and approved the final manuscript.
Acknowledgements
This study was supported by the Conselho Nacional de Desenvolvimento
Científico e Tecnológico (www.cnpq.br) grant number 302774/2009-2 to RRB
and 301609/2007-1 to MACS and by the Fundação de Amparo à Pesquisa do
Estado de São Paulo (www.fapesp.br) to MFL and DQC.
Author details
1Laboratório de Citogenética Humana, Instituto de Ciências Biológicas,
Universidade Federal do Pará, CEP: 66073-000, Belém, PA, Brazil. 2Disciplina
de Genética, Departamento de Morfologia e Genética, Universidade Federal
de São Paulo, Rua Botucatu 740, CEP 04023-900, São Paulo, SP, Brazil.
3Unidade de Alta Complexidade em Oncologia, Hospital Universitário João
de Barros Barreto, Universidade Federal do Pará, CEP: 60673-000, Belém, PA,
Brazil. 4Laboratório de Genética Molecular, Departamento de Patologia e
Medicina Forense, Escola de Medicina, Universidade Federal do Ceará, CEP:
60020-181, Fortaleza, CE, Brazil.
Received: 13 March 2012 Accepted: 28 June 2012
Published: 6 July 2012
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61(2):69–90.
2. Instituto Nacional de Câncer - INCA: Estimate/2010 - Incidence of Cancer in
Brazil. Rio de Janeiro: Instituto Nacional de Câncer/Ministério da Saúde;
2009:98.
3. Correa P: Human gastric carcinogenesis: a multistep and multifactorial
process–First American Cancer Society Award Lecture on Cancer
Epidemiology and Prevention. Cancer Res 1992, 52(24):6735–6740.
4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM,
Wright WE, Weinrich SL, Shay JW: Specific association of human
telomerase activity with immortal cells and cancer. Science 1994,
266(5193):2011–2015.
5. Artandi SE, DePinho RA: Mice without telomerase: what can they teach us
about human cancer? Nat Med 2000, 6(8):852–855.
Silva et al. BMC Gastroenterology 2012, 12:85 Page 7 of 8
http://www.biomedcentral.com/1471-230X/12/856. Kyo S, Takakura M, Fujiwara T, Inoue M: Understanding and exploiting
hTERT promoter regulation for diagnosis and treatment of human
cancers. Cancer Sci 2008, 99(8):1528–1538.
7. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR: MYC and
gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008,
14(39):5962–5968.
8. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A,
Amati B: Genomic targets of the human c-Myc protein. Genes Dev 2003,
17(9):1115–1129.
9. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F: The c-Myc
target gene network. Semin Cancer Biol 2006, 16(4):253–264.
10. Szymanska K, Hainaut P: TP53 and mutations in human cancer. Acta
Biochim Pol 2003, 50(1):231–238.
11. Vousden KH, Ryan KM: p53 and metabolism. Nat Rev Cancer 2009,
9(10):691–700.
12. Khayat AS, Guimaraes AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF,
Faria MH, Rabenhorst SH, Assumpcao PP, Demachki S, et al:
Interrelationship between TP53 gene deletion, protein expression
and chromosome 17 aneusomy in gastric adenocarcinoma.
BMC Gastroenterol 2009, 9:55.
13. Pelengaris S, Rudolph B, Littlewood T: Action of Myc in vivo - proliferation
and apoptosis. Curr Opin Genet Dev 2000, 10(1):100–105.
14. Dazard JE, Piette J, Basset-Seguin N, Blanchard JM, Gandarillas A: Switch
from p53 to MDM2 as differentiating human keratinocytes lose their
proliferative potential and increase in cellular size. Oncogene 2000,
19(33):3693–3705.
15. Lan J, Xiong YY, Lin YX, Wang BC, Gong LL, Xu HS, Guo GS: Helicobacter
pylori infection generated gastric cancer through p53-Rb tumor-
suppressor system mutation and telomerase reactivation.
World J Gastroenterol 2003, 9(1):54–58.
16. Wang W, Luo HS, Yu BP: Expression of NF-kappaB and human telomerase
reverse transcriptase in gastric cancer and precancerous lesions.
World J Gastroenterol 2004, 10(2):177–181.
17. Cassaro M, Rugge M, Tieppo C, Giacomelli L, Velo D, Nitti D, Farinati F:
Indefinite for non-invasive neoplasia lesions in gastric intestinal
metaplasia: the immunophenotype. J Clin Pathol 2007, 60(6):615–621.
18. Gulmann C, Lantuejoul S, Grace A, Leader M, Patchett S, Kay E: Telomerase
activity in proximal and distal gastric neoplastic and preneoplastic
lesions using immunohistochemical detection of hTERT.
Dig Liver Dis 2005, 37(6):439–445.
19. Jong HS, Park YI, Kim S, Sohn JH, Kang SH, Song SH, Bang YJ, Kim NK:
Up-regulation of human telomerase catalytic subunit during gastric
carcinogenesis. Cancer 1999, 86(4):559–565.
20. Gigek CO, Leal MF, Silva PN, Lisboa LC, Lima EM, Calcagno DQ, Assumpcao PP,
Burbano RR, Smith MA: hTERT methylation and expression in gastric cancer.
Biomarkers 2009, 14(8):630–636.
21. Calcagno DQ, Leal MF, Demachki S, Araujo MT, Freitas FW: SD Oliveira e,
Assumpcao PP, Ishak G, de Arruda Cardoso Smith M, Burbano RR: MYC
in gastric carcinoma and intestinal metaplasia of young adults.
Cancer Genet Cytogenet 2010, 202(1):63–66.
22. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S,
Assumpcao PP, Faria MH, Rabenhorst SH, Ferreira MV, et al:
Interrelationship between chromosome 8 aneuploidy, C-MYC
amplification and increased expression in individuals from northern
Brazil with gastric adenocarcinoma. World J Gastroenterol 2006,
12(38):6207–6211.
23. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimaraes AC,
Calcagno DQ, Khayat AS, Assumpcao PP, de Arruda Cardoso Smith M, Burbano
RR: Interrelationship between MYC gene numerical aberrations and protein
expression in individuals from northern Brazil with early gastric
adenocarcinoma. Cancer Genet Cytogenet 2008, 181(1):31–35.
24. da Costa Jde F, Leal MF, Silva TC, Andrade Junior EF, Rezende AP, Muniz JA,
Lacreta Junior AC, Assumpcao PP, Calcagno DQ, Demachki S, et al:
Experimental gastric carcinogenesis in Cebus apella nonhuman
primates. PLoS One 2011, 6(7):e21988.
25. Han JC, Zhang KL, Chen XY, Jiang HF, Kong QY, Sun Y, Wu ML, Huang L, Li H,
Liu J: Expression of seven gastric cancer-associated genes and its relevance
for Wnt, NF-kappaB and Stat3 signaling. APMIS 2007,
115(12):1331–1343.
26. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J: Expression of
nuclear factor-kappa B and target genes in gastric precancerous lesionsand adenocarcinoma: association with Helicobactor pylori cagA (+)
infection. World J Gastroenterol 2004, 10(4):491–496.
27. Zhang GX, Gu YH, Zhao ZQ, Xu SF, Zhang HJ, Wang HD, Hao B: Coordinate
increase of telomerase activity and c-Myc expression in Helicobacter
pylori-associated gastric diseases. World J Gastroenterol 2004,
10(12):1759–1762.
28. Assumpcao PP, Ishak G, Chen ES, Takeno SS, Leal MF, Guimaraes AC,
Calcagno DQ, Khayat AS, Demachki S, Smith MA, et al: Numerical
aberrations of chromosome 8 detected by conventional cytogenetics
and fluorescence in situ hybridization in individuals from northern Brazil
with gastric adenocarcinoma. Cancer Genet Cytogenet 2006, 169(1):45–49.
29. Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS,
Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification
as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH
study in Brazil. Anticancer Res 2006, 26(4B):2909–2914.
30. Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A,
Burbano RR: Aneuploidy of chromosome 8 and C-MYC amplification in
individuals from northern Brazil with gastric adenocarcinoma.
Anticancer Res 2005, 25(6B):4069–4074.
31. Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB,
Assumpcao PP: De Arruda Cardoso Smith M, Burbano RR: MYC insertions in
diffuse-type gastric adenocarcinoma. Anticancer Res 2009, 29(7):2479–2483.
32. Leal MF, Calcagno DQ: da Borges Costa JF, Silva TC, Khayat AS, Chen ES,
Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR: MYC, TP53,
and chromosome 17 copy-number alterations in multiple gastric cancer
cell lines and in their parental primary tumors. J Biomed Biotechnol 2011,
2011:631268.
33. Leal MF: Nascimento JL Martins do, da Silva CE, Vita Lamarao MF,
Calcagno DQ, Khayat AS, Assumpcao PP, Cabral IR, de Arruda Cardoso
Smith M, Burbano RR: Establishment and conventional cytogenetic
characterization of three gastric cancer cell lines. Cancer Genet Cytogenet
2009, 195:(1)85–91.
34. Ribeiro HF, Alcantara DF, Matos LA, Sousa JM, Leal MF, Smith MA, Burbano RR,
Bahia MO: Cytogenetic characterization and evaluation of c-MYC gene
amplification in PG100, a new Brazilian gastric cancer cell line.
Braz J Med Biol Res 2010, 43(8):717–721.
35. Costa Guimaraes A, Goncalves Quintana L, Ferreira Leal M, Satomi Takeno S,
Pimentel Assumpcao P, Moura Lima E, Salim Khayat A, Suchi Chen E, de
Arruda Cardoso Smith M, Rodriguez Burbano R: Aneuploidy of
chromosome 8 detected by fluorescence in situ hybridisation in ACP01
cell line gastric adenocarcinoma. Clin Exp Med 2006, 6(3):129–133.
36. Cesar AC, Borim AA, Caetano A, Cury PM, Silva AE: Aneuploidies, deletion,
and overexpression of TP53 gene in intestinal metaplasia of patients
without gastric cancer. Cancer Genet Cytogenet 2004, 153(2):127–132.
37. Morgan C, Jenkins GJ, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM:
Detection of p53 mutations in precancerous gastric tissue. Br J Cancer
2003, 89(7):1314–1319.
38. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: p53
mutation in gastric cancer: a genetic model for carcinogenesis is
common to gastric and colorectal cancer. Int J Cancer 1993,
54(5):759–764.
39. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in
gastric precancerous lesions. Am J Pathol 1994, 144(3):511–517.
40. Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E:
Helicobacter pylori infection and oncogene expressions in gastric
carcinoma and its precursor lesions. Dig Dis Sci 2002, 47(1):107–113.
41. Targa AC, Cesar AC, Cury PM, Silva AE: Apoptosis in different gastric
lesions and gastric cancer: relationship with Helicobacter pylori,
overexpression of p53 and aneuploidy. Genet Mol Res 2007, 6(3):554–565.
42. Williams L, Jenkins GJ, Doak SH, Fowler P, Parry EM, Brown TH, Griffiths AP,
Williams JG, Parry JM: Fluorescence in situ hybridisation analysis of
chromosomal aberrations in gastric tissue: the potential involvement of
Helicobacter pylori. Br J Cancer 2005, 92(9):1759–1766.
43. Leal MF, Calcagno DQ: da Costa JF Borges, Silva TC, Khayat AS, Chen ES,
Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR: MYC, TP53,
and chromosome 17 copy-number alterations in multiple gastric cancer
cell lines and in their parental primary tumors. J Biomed Biotechnol 2010,
2011:631268.
44. Bacchi MM, Bacchi CE, Alvarenga M, Miranda R, Chen YY, Weiss LM: Burkitt's
lymphoma in Brazil: strong association with Epstein-Barr virus. Mod
Pathol 1996, 9(1):63–67.
Silva et al. BMC Gastroenterology 2012, 12:85 Page 8 of 8
http://www.biomedcentral.com/1471-230X/12/8545. Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S: Sensitive
detection of Helicobacter pylori by using polymerase chain reaction.
J Clin Microbiol 1992, 30(1):192–200.
46. Arocho A, Chen B, Ladanyi M, Pan Q: Validation of the 2-DeltaDeltaCt
calculation as an alternate method of data analysis for quantitative PCR
of BCR-ABL P210 transcripts. Diagn Mol Pathol 2006, 15(1):56–61.
doi:10.1186/1471-230X-12-85
Cite this article as: Silva et al.: hTERT, MYC and TP53 deregulation in
gastric preneoplastic lesions. BMC Gastroenterology 2012 12:85.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
